Phospho-EGFR (Tyr1173) Polyclonal Antibody | Invitrogen 44-794G product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Phospho-EGFR (Tyr1173) Polyclonal Antibody

catalog :

44-794G

quantity :

100 µL

price :

US 500.00

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

antigen modification :

phosphorylated

reactivity :

human, mouse, rat

application :

western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section

more info or order :

Invitrogen product webpage

citations: 15

Published Application/Species/Sample/Dilution	Reference
western blot; human; fig 5b	Grugan K, Dorn K, Jarantow S, Bushey B, Pardinas J, Laquerre S, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs. 2017;9:114-126 pubmed publisher
	Wisniewski D, Liyasova M, Korrapati S, Zhang X, Ratnayake S, Chen Q, et al. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth. J Biol Chem. 2022;299:102766 pubmed publisher
	Moritz S, Krause M, Schlatter J, Cordes N, Vehlow A. Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR. Cancers (Basel). 2021;13: pubmed publisher
	Fu E, Liu T, Yu S, Chen X, Song L, Lou H, et al. M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB‑EGF. Oncol Rep. 2020;44:698-710 pubmed publisher
	Korolkova O, Widatalla S, Whalen D, Nangami G, Abimbola A, Williams S, et al. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS ONE. 2020;15:e0231711 pubmed publisher
	Bonus M, Sommerfeld A, Qvartskhava N, Gorg B, Ludwig B, Kessler H, et al. Evidence for functional selectivity in TUDC- and norUDCA-induced signal transduction via α5β1 integrin towards choleresis. Sci Rep. 2020;10:5795 pubmed publisher
	Wong R, Luo X, Lu M, An Z, Haas Kogan D, Phillips J, et al. Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma. Cancer Res. 2020;80:709-718 pubmed publisher
	Clemente L, Boeldt D, Grummer M, Morita M, Morgan T, Wiepz G, et al. Adenoviral transduction of EGFR into pregnancy-adapted uterine artery endothelial cells remaps growth factor induction of endothelial dysfunction. Mol Cell Endocrinol. 2020;499:110590 pubmed publisher
	Tabtimmai L, Suphakun P, Srisook P, Kiriwan D, Phanthong S, Kiatwuthinon P, et al. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. J Cell Biochem. 2019;120:18077-18087 pubmed publisher
	Sakamoto K, Ozaki T, Ko Y, Tsai C, Gong Y, Morozumi M, et al. Glycan sulfation patterns define autophagy flux at axon tip via PTPRσ-cortactin axis. Nat Chem Biol. 2019;15:699-709 pubmed publisher
	Longton E, Schmit K, Fransolet M, Clement F, Michiels C. Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma. Front Oncol. 2018;8:432 pubmed publisher
	Nikonova A, Deneka A, Eckman L, Kopp M, Hensley H, Egleston B, et al. Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease. Front Oncol. 2015;5:228 pubmed publisher
	Bollu L, Katreddy R, Blessing A, Pham N, Zheng B, Wu X, et al. Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation. Oncotarget. 2015;6:34992-5003 pubmed publisher
	Ramirez U, Nikonova A, Liu H, Pecherskaya A, Lawrence S, Serebriiskii I, et al. Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization. BMC Cancer. 2015;15:436 pubmed publisher
	Rios Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015;14:1637-49 pubmed publisher

product information

Product Type :

Antibody

Product Name :

Phospho-EGFR (Tyr1173) Polyclonal Antibody

Catalog # :

44-794G

Quantity :

100 µL

Price :

US 500.00

Clonality :

Polyclonal

Purity :

Antigen affinity chromatography

Host :

Rabbit

Reactivity :

Human, Mouse, Rat

Applications :

Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:10-1:100, peptide-ELISA: Assay-dependent, Western Blot: 1:1,000

Species :

Human, Mouse, Rat

Isotype :

IgG

Storage :

-20°C

Description :

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Immunogen :

The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human EGFR that contains tyrosine 1173. The sequence is conserved in mouse and rat.

Format :

Liquid

Applications w/Dilutions :

Immunocytochemistry: 1:100-1:500, Immunohistochemistry (Paraffin): 1:10-1:100, peptide-ELISA: Assay-dependent, Western Blot: 1:1,000

Aliases :

2.7.10.1; 9030024J15Rik; AI552599; avian erythroblastic leukemia viral (v-erbB) oncogene homolog; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EC 2.7.10.1; egf receptor; Egfr; EGFR-related peptide; epidermal growth factor receptor; epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); ERBB; ERBB1; ErbB-1; erb-b2 receptor tyrosine kinase 1; Errb1; Errp; HER1; kinase EGFR; mENA; NISBD2; Oncogene ERBB; PIG61; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; Urogastrone; wa2; wa-2; Wa5; waved 2

more info or order :

Invitrogen product webpage